Early prediction of decompensation (EPOD) score: Non-invasive determination of cirrhosis decompensation risk.
cirrhosis
electronic health records
proportional hazards models
regression analysis
risk scores
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
10
12
2021
received:
15
09
2021
accepted:
05
01
2022
pubmed:
11
1
2022
medline:
4
3
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Decompensation is a hallmark of disease progression in cirrhotic patients. Early detection of a phase transition from compensated cirrhosis to decompensation would enable targeted therapeutic interventions potentially extending life expectancy. This study aims to (a) identify the predictors of decompensation in a large, multicentric cohort of patients with compensated cirrhosis, (b) to build a reliable prognostic score for decompensation and (c) to evaluate the score in independent cohorts. Decompensation was identified in electronic health records data from 6049 cirrhosis patients in the IBM Explorys database training cohort by diagnostic codes for variceal bleeding, encephalopathy, ascites, hepato-renal syndrome and/or jaundice. We identified predictors of clinical decompensation and developed a prognostic score using Cox regression analysis. The score was evaluated using the IBM Explorys database validation cohort (N = 17662), the Penn Medicine BioBank (N = 1326) and the UK Biobank (N = 317). The new Early Prediction of Decompensation (EPOD) score uses platelet count, albumin, and bilirubin concentration. It predicts decompensation during a 3-year follow-up in three validation cohorts with AUROCs of 0.69, 0.69 and 0.77, respectively, and outperforms the well-known MELD and Child-Pugh score in predicting decompensation. Furthermore, the EPOD score predicted the 3-year probability of decompensation. The EPOD score provides a prediction tool for the risk of decompensation in patients with cirrhosis that outperforms well-known cirrhosis scores. Since EPOD is based on three blood parameters, only, it provides maximal clinical feasibility at minimal costs.
Sections du résumé
BACKGROUND & AIMS
Decompensation is a hallmark of disease progression in cirrhotic patients. Early detection of a phase transition from compensated cirrhosis to decompensation would enable targeted therapeutic interventions potentially extending life expectancy. This study aims to (a) identify the predictors of decompensation in a large, multicentric cohort of patients with compensated cirrhosis, (b) to build a reliable prognostic score for decompensation and (c) to evaluate the score in independent cohorts.
METHODS
Decompensation was identified in electronic health records data from 6049 cirrhosis patients in the IBM Explorys database training cohort by diagnostic codes for variceal bleeding, encephalopathy, ascites, hepato-renal syndrome and/or jaundice. We identified predictors of clinical decompensation and developed a prognostic score using Cox regression analysis. The score was evaluated using the IBM Explorys database validation cohort (N = 17662), the Penn Medicine BioBank (N = 1326) and the UK Biobank (N = 317).
RESULTS
The new Early Prediction of Decompensation (EPOD) score uses platelet count, albumin, and bilirubin concentration. It predicts decompensation during a 3-year follow-up in three validation cohorts with AUROCs of 0.69, 0.69 and 0.77, respectively, and outperforms the well-known MELD and Child-Pugh score in predicting decompensation. Furthermore, the EPOD score predicted the 3-year probability of decompensation.
CONCLUSIONS
The EPOD score provides a prediction tool for the risk of decompensation in patients with cirrhosis that outperforms well-known cirrhosis scores. Since EPOD is based on three blood parameters, only, it provides maximal clinical feasibility at minimal costs.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
640-650Subventions
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. The Lancet. 2015;385(9963):117-171.
Zou B, Yeo YH, Jeong D, et al. A Nationwide study of inpatient admissions, mortality, and costs for patients with cirrhosis from 2005 to 2015 in the USA. Digestive Diseases and Sciences. 2020;65(5):1520-1528.
Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine. 2014;12:145.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
D’amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of Hepatology. 2006;44(1):217-231.
D’amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Digestive Diseases and Sciences. 1986;31(5):468-475.
Mansour D, Mcpherson S. Management of decompensated cirrhosis. Clinical Medicine (London, England). 2018;18(Suppl 2):s60-s65.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. The British Journal of Surgery. 1973;60(8):646-649.
Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481-488.
Kim W R, Kamath P S. Hepatic vein pressure gradient >10 mm hg: prognostic or reflective? Gastroenterology 2008; 134(2): 641; author reply 41-2.
Bothou C, Rüschenbaum S, Kubesch A, et al. Anemia and systemic inflammation rather than arterial circulatory dysfunction predict decompensation of liver cirrhosis. J Clin Med. 2020;9(5):1263.
Kubesch A, Quenstedt L, Saleh M, et al. Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: a prospective cohort study. PLoS One. 2018;13(11):e0207162.
[cited January 15, 2021]; Available from: https://www.ibm.com/products/explorys-ehr-data-analysis-tools
Child CG Surgery and portal hypertension. In The liver and portal hypertension 1964.
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2015;33(6):550-558.
Roayaie S, Jibara G, Berhane S, et al. PALBI-an objective score based on platelets, Albumin & Bilirubin Stratifies HCC patients Undergoing Resection & Ablation Better than Child’s classification. The liver meeting. American Association for the Study of Liver Diseases; 2015.
Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144(1):102-11.e1.
Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World Journal of Gastroenterology. 2009;15(37):4653-4658.
Shin JY, Kim MJ, Kim ES, et al. Association between serum calcium and phosphorus concentrations with non-alcoholic fatty liver disease in Korean population. Journal of Gastroenterology and Hepatology. 2015;30(4):733-741.
Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgraduate Medical Journal. 2016;92(1086):223-234.
Arjal R, Trotter JF. International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clinics in Liver Disease. 2009;13(1):67-71.
Kovacs MJ, Wong A, Mackinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thrombosis and Haemostasis. 1994;71(6):727-730.
Robert A, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology. 1996;24(6):1392-1394.
Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. American Journal of Transplantation. 2007;7(6):1624-1628.
Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UKbiobank participants with those of the general population. American Journal of Epidemiology. 2017;186(9):1026-1034.